RLMD

Relmada Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 6/10
  • Value↑ 5/10
Relmada Therapeutics sales and earnings growth
RLMD Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 45.28%
  • FCF Y/Y↑ 11.53%
Relmada Therapeutics gross and profit margin trends
RLMD Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -154.55%
Relmada Therapeutics net debt vs free cash flow
RLMD Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Relmada Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks